![conference banner](/images/conference-banner.jpeg)
Abstract
Background: The generic name “flavonolignan” was created in 1968 for a relatively small class of naturally occurring hybrid molecules biogenetically originated from ubiquitous flavonoids and lignans (phenylpropanoids). The first group of flavonolignans was extracted from Silybum marianum that has long been used for hepatoprotection. Recently, the medicinal merit of flavonolignans has been extended to the prostate cancer management.
Methods: Systematic interpretation and summarization of the relevant literature.
Results: Over forty naturally occurring flavonolignans have so far been obtained from various plants. Certain flavonolignans have been demonstrated by in vitro cell-based and in vivo animal-based experiments, and human clinical studies i) to possess effective chemopreventive function against various tumor promoters; ii) to show the anti-angiogenic efficacy; iii) to have potential in treating prostate cancer; iv) to sensitize prostate tumors to chemotherapeutic agents through down-regulation of P-glycoprotein and other mechanisms; and v) to be used by prostate cancer patients to protect or treat the hepatotoxicity caused by several chemotherapies. Certain flavonolignans can synergize with well-established chemotherapeutic agents for prostate cancer.
Conclusion: This review provides a systematic and in-depth overview of the promise and potential of flavonolignans in prostate cancer management, which covers their chemopreventive effect, chemotherapeutic treatment, mechanisms of actions, synthetic derivatives, structure-activity relationships, and the difference in inhibiting prostate cancer cell proliferation between certain flavonoligans and their respective flavonoid counterpart. This summarization aims to provide valuable insights into further and rational development of flavonolignans for prostate cancer management by interpreting the data reported in the literature.
Keywords: Prostate cancer, Flavonolignan, Mechanism of action, Chemotherapeutic agent, Structure-activity relationships, Flavonoid.
Current Medicinal Chemistry
Title:The Potential of Flavonolignans in Prostate Cancer Management
Volume: 23 Issue: 34
Author(s): Bao Vue and Qiao-Hong Chen
Affiliation:
Keywords: Prostate cancer, Flavonolignan, Mechanism of action, Chemotherapeutic agent, Structure-activity relationships, Flavonoid.
Abstract: Background: The generic name “flavonolignan” was created in 1968 for a relatively small class of naturally occurring hybrid molecules biogenetically originated from ubiquitous flavonoids and lignans (phenylpropanoids). The first group of flavonolignans was extracted from Silybum marianum that has long been used for hepatoprotection. Recently, the medicinal merit of flavonolignans has been extended to the prostate cancer management.
Methods: Systematic interpretation and summarization of the relevant literature.
Results: Over forty naturally occurring flavonolignans have so far been obtained from various plants. Certain flavonolignans have been demonstrated by in vitro cell-based and in vivo animal-based experiments, and human clinical studies i) to possess effective chemopreventive function against various tumor promoters; ii) to show the anti-angiogenic efficacy; iii) to have potential in treating prostate cancer; iv) to sensitize prostate tumors to chemotherapeutic agents through down-regulation of P-glycoprotein and other mechanisms; and v) to be used by prostate cancer patients to protect or treat the hepatotoxicity caused by several chemotherapies. Certain flavonolignans can synergize with well-established chemotherapeutic agents for prostate cancer.
Conclusion: This review provides a systematic and in-depth overview of the promise and potential of flavonolignans in prostate cancer management, which covers their chemopreventive effect, chemotherapeutic treatment, mechanisms of actions, synthetic derivatives, structure-activity relationships, and the difference in inhibiting prostate cancer cell proliferation between certain flavonoligans and their respective flavonoid counterpart. This summarization aims to provide valuable insights into further and rational development of flavonolignans for prostate cancer management by interpreting the data reported in the literature.
Export Options
About this article
Cite this article as:
Vue Bao and Chen Qiao-Hong, The Potential of Flavonolignans in Prostate Cancer Management, Current Medicinal Chemistry 2016; 23 (34) . https://dx.doi.org/10.2174/0929867323666160823151833
DOI https://dx.doi.org/10.2174/0929867323666160823151833 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy An Update on Poly(ADP-ribose) Polymerase I-A Brief Review
Mini-Reviews in Medicinal Chemistry Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway
Current Drug Targets Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
Current Cancer Drug Targets Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Clinical Development of Palbociclib: An Overview
Medicinal Chemistry Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics
Current Medicinal Chemistry Current Status of Hedgehog Signaling Inhibitors
Current Topics in Medicinal Chemistry Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Knockdown of Insulin-Like Growth Factor I Receptor Inhibits the Growth and Enhances Chemo-Sensitivity of Liver Cancer Cells
Current Cancer Drug Targets Phytochemical Constituents of Annona reticulata and their Cytotoxic Activity
Letters in Organic Chemistry Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Surgical Complications of Hyperglycaemia
Current Diabetes Reviews NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets Protein Cysteine Modifications: (2) Reactivity Specificity and Topics of Medicinal Chemistry and Protein Engineering
Current Medicinal Chemistry The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations
Current Medicinal Chemistry Duloxetine in the Treatment of Depression: An Overview
Central Nervous System Agents in Medicinal Chemistry Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening